Werewolf <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Promising Phase 1 Data for WTX-124 and WTX-330 in Advanced Cancer Trials
Werewolf Therapeutics Inc. announced updates on its pipeline, including new clinical data for its INDUKINE™ programs. Initial Phase 1b expansion arm data for WTX-124 showed a 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with a favorable tolerability profile. Initial data from the ongoing Phase 1b/2 trial of WTX-330 demonstrated additional evidence of antitumor activity and a highly favorable tolerability profile. The company plans to provide an additional Phase 1/1b data update for WTX-124 and complete Part A of the Phase 1b/2 clinical trial for WTX-330 in the first half of 2026. Werewolf Therapeutics is also progressing its INDUCER™ T cell engager platform, with plans for two IND filings by mid-2027 for WTX-1011 and WTX-2022.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604461-en) on December 18, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。